Startups
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
Overview
Location
United States
Employees
51-200
Total raised
$321M
Founded date
2019
Investors 4
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| BioImpact Capital | bioimpactcapital.com | |
| Mar 4, 2021 | Taiho Ventures | taihoventures.com |
| MPM BioImpact | mpmbioimpact.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Feb 25, 2021 | Series A round | $100M |
Mentions in press and media 26
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 31, 2026 | Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs | Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness. The deal is the latest from Lilly, which is using its GLP-1 windfall to place mo... |
| Feb 27, 2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| Feb 23, 2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| Feb 11, 2026 | Eli Lilly Secures Future with Orna Therapeutics Acquisition | Eli Lilly acquired Orna Therapeutics. The deal totals up to $2.4 billion. This secures groundbreaking circular RNA technology. Orna pioneers *in vivo* cell engineering. Their platform allows the body to generate therapies internally. This b... |
| Feb 9, 2026 | Haveli Investments Acquires Budge Studios from General Atlantic | Haveli Investments, an Austin-based private equity firm specializing in technology and gaming, acquired Budge Studios, a Montreal, Canada-based developer of digital interactive entertainment for children, from General Atlantic. The amount o... |
| Feb 9, 2026 | Eli Lilly and Company to Acquire Orna Therapeutics, For Up To $2.4 Billion | Eli Lilly and Company (NYSE: LLY) is to acquire Orna Therapeutics, Inc., a Waterotown, Mass.-based biotechnology company dedicated to engineering immune cells in vivo. Under the terms of the agreement, Lilly will acquire Orna, and Orna shar... |
| Feb 9, 2026 | Фармкомпания Eli Lilly покупает американскую биотех-компанию Orna Therapeutics за $2,4 млрд | Американская фармацевтическая компания Eli Lilly (LLY.N) согласилась купить биотехнологическую компанию Orna Therapeutics за $2,4 млрд наличными, получив доступ к технологии, которая позволяет использовать собственные клетки пациентов для с... |
| Aug 23, 2024 | Abogen announced development of Cis-System-based circular RNAs | SUZHOU, China, Aug. 23, 2024 /PRNewswire/ -- Abogen Biosciences ("Abogen" or the "Company") announced a publication titled "Efficient circularization of protein-encoding RNAs via a novel cis-splicing system " i... |
| Jul 30, 2024 | Orna Therapeutics Appoints Nobel Laureate Carolyn Bertozzi, Ph.D., to Scientific Advisory Board | WATERTOWN, Mass., July 30, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines, including panCAR™ in vivo CAR therapies for oncology and autoimmune dise... |
Show more
Reviews 0
FAQ about Orna Therapeutics
When was Orna Therapeutics founded?
Orna Therapeutics was founded in 2019.
How much funding has Orna Therapeutics raised?
Orna Therapeutics has raised $321M in total across 2 funding rounds.
What funding rounds has Orna Therapeutics raised?
Parsers VC lists 2 funding rounds of Orna Therapeutics, among them a Series A round of $100M on Feb 25, 2021.
Who has invested in Orna Therapeutics?
Parsers VC lists 4 investors of Orna Therapeutics, among them Taiho Ventures, BioImpact Capital and MPM BioImpact.
What has the press written about Orna Therapeutics?
Parsers VC has collected 26 articles mentioning Orna Therapeutics, among them “Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs” (Mar 31, 2026) and “Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future” (Feb 27, 2026).
Is Orna Therapeutics still active?
Yes, Orna Therapeutics is active; its latest activity on Parsers VC dates from Apr 20, 2026.